Neurimmune Sells A Portion Of Its Royalty Interest In Cliramitug To Royalty Pharma
RPRX•Royalty interest sale to Royalty Pharma
- Neurimmune sold a portion of its royalty interest in cliramitug to Royalty Pharma for up to $425 million.
- In the first quarter of 2027, Royalty Pharma will provide another $125 million in cash to the company.
